INMD Quote, Financials, Valuation and Earnings

Can Fite Biofarma has a net margin of 39.15% compared to InMode's net margin of --. InMode's return on equity of 20.14% beat Can Fite Biofarma's return on equity of --.

InMode has a consensus price target of --, signalling upside risk potential of 24.9%. On the other hand Can Fite Biofarma has an analysts' consensus of -- which suggests that it could grow by 845.95%. Given that Can Fite Biofarma has higher upside potential than InMode, analysts believe Can Fite Biofarma is more attractive than InMode.

InMode has a beta of 2.074, which suggesting that the stock is 107.386% more volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.764%.

InMode has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.

InMode quarterly revenues are $130.2M, which are larger than Can Fite Biofarma quarterly revenues of --. InMode's net income of $51M is higher than Can Fite Biofarma's net income of --. Notably, InMode's price-to-earnings ratio is 9.23x while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode is 3.39x versus 13.42x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.

Compugen has a net margin of 39.15% compared to InMode's net margin of 7.45%. InMode's return on equity of 20.14% beat Compugen's return on equity of 2.69%.

InMode has a consensus price target of --, signalling upside risk potential of 24.9%. On the other hand Compugen has an analysts' consensus of -- which suggests that it could grow by 159.74%. Given that Compugen has higher upside potential than InMode, analysts believe Compugen is more attractive than InMode.

InMode has a beta of 2.074, which suggesting that the stock is 107.386% more volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.818%.

InMode has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.

InMode quarterly revenues are $130.2M, which are larger than Compugen quarterly revenues of $17.1M. InMode's net income of $51M is higher than Compugen's net income of $1.3M. Notably, InMode's price-to-earnings ratio is 9.23x while Compugen's PE ratio is 51.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode is 3.39x versus 2.30x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of 39.15% compared to InMode's net margin of --. InMode's return on equity of 20.14% beat BiomX's return on equity of --.

InMode has a consensus price target of --, signalling upside risk potential of 24.9%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1029.03%. Given that BiomX has higher upside potential than InMode, analysts believe BiomX is more attractive than InMode.

InMode has a beta of 2.074, which suggesting that the stock is 107.386% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.

InMode has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

InMode quarterly revenues are $130.2M, which are larger than BiomX quarterly revenues of --. InMode's net income of $51M is higher than BiomX's net income of $9.6M. Notably, InMode's price-to-earnings ratio is 9.23x while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode is 3.39x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of 39.15% compared to InMode's net margin of -1804.3%. InMode's return on equity of 20.14% beat Pluri's return on equity of -438.78%.

InMode has a consensus price target of --, signalling upside risk potential of 24.9%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 563.9%. Given that Pluri has higher upside potential than InMode, analysts believe Pluri is more attractive than InMode.

InMode has a beta of 2.074, which suggesting that the stock is 107.386% more volatile than S&P 500. In comparison Pluri has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.245%.

InMode has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

InMode quarterly revenues are $130.2M, which are larger than Pluri quarterly revenues of $326K. InMode's net income of $51M is higher than Pluri's net income of -$5.9M. Notably, InMode's price-to-earnings ratio is 9.23x while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode is 3.39x versus 42.82x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.